Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Enliven Therapeutics priced an upsized underwritten public offering of 8,933,334 shares of common stock at $37.50 per share and pre-funded warrants to purchase up to 1,733,333 shares at $37.499 each. All securities are being sold by the company, with expected gross proceeds of about $400.0 million.
Net proceeds are expected to be approximately $376.0 million, or $432.4 million if underwriters fully exercise a 1,600,000-share option. The offering, made off an effective Form S-3ASR shelf, is expected to close on or about June 15, 2026, subject to customary conditions. The pre-funded warrants are exercisable immediately at $0.001 per share and include ownership caps between 4.99% and 19.99%.
Enliven Therapeutics is offering 8,933,334 shares of common stock and pre-funded warrants to purchase 1,733,333 shares. The public offering price per share is $37.50 and each pre-funded warrant has an exercise price of $0.001. Delivery is expected on or about June 15, 2026. Net proceeds to the company are estimated at approximately $376.0M before expenses, or $432.4M if the underwriters’ 30-day option for an additional 1,600,000 shares is exercised in full. The prospectus supplement notes an ownership limitation on exercises (default 4.99%, holder-elected 9.99%, increaseable up to 19.99% with notice) and that pre-funded warrants are not listed and have no established trading market. The company expects to use proceeds to advance ELVN-001 clinical development and for working capital and general corporate purposes.
Enliven Therapeutics is offering $250,000,000 of common stock and pre-funded warrants as part of a shelf offering. The prospectus supplement states the offering size is $250,000,000 and that pre-funded warrants will have an exercise price of $0.001 per share.
The document discloses 60,889,655 shares outstanding as of March 31, 2026, a historical net tangible book value of $453.4 million (or $7.45 per share as of March 31, 2026), and an underwriters’ option to purchase up to an additional $37,500,000. Net proceeds are described as intended to fund ELVN-001 clinical development, initial commercial readiness and general corporate purposes, and management believes available capital will fund operations into 2030.
Enliven Therapeutics announced updated positive Phase 1 data for its CML drug candidate ELVN-001 and reported key outcomes from an End-of-Phase 1 meeting with the FDA. In Phase 1b, overall major molecular response (MMR) reached 54% in evaluable patients and 61% in the 80 mg once-daily cohort by week 24, with 100% of patients who achieved MMR maintaining it. Response rates by 24 weeks were higher in patients treated earlier in their TKI sequence, including those previously on asciminib. The safety profile was described as favorable and consistent with ELVN-001’s high selectivity, based on 161 enrolled patients and a median treatment duration of 35 weeks. Enliven and the FDA reached alignment on 80 mg once daily as the recommended Phase 3 dose and on a second-line-or-later patient population for the planned ENABLE-2 pivotal trial, which the company expects to initiate in the second half of the year.
Enliven Therapeutics, Inc. reported the results of its annual stockholder meeting and an amendment to its charter. Stockholders approved increasing authorized common stock from 100,000,000 to 200,000,000 shares, and the company filed a Certificate of Amendment making total authorized capital 210,000,000 shares.
Two Class III directors, Richard Fair and Lori Kunkel, were elected to terms ending at the 2029 meeting. Stockholders ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, approved executive compensation on an advisory basis, and supported holding future say‑on‑pay votes every year.
Enliven Therapeutics director Lori Anne Kunkel reported open-market sales of 10,000 shares of Enliven Therapeutics, Inc. common stock on June 5, 2026, executed in multiple trades under a Rule 10b5-1 trading plan adopted on March 6, 2026.
The shares were sold in three transactions at weighted average prices of $34.2794, $35.3573, and $35.8187 per share. After these sales, she held 51,884 shares of common stock directly.
Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins reported both stock sales and an option exercise in the company’s shares. On May 18, 2026, she sold a total of 5,000 shares of Common Stock in open-market transactions at prices including $39.5340, $40.2473 and $41.2052 per share.
On the same date, she exercised a stock option to acquire 5,000 shares of Common Stock at an exercise price of $2.4800 per share. Following these transactions, she directly owned 25,000 shares of Common Stock and held 126,268 stock options exercisable at $2.4800 per share, expiring on June 17, 2031. The filing notes that the option exercise and related sales were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.
Enliven Therapeutics, Inc. submitted a notice relating to the proposed sale of 15,000 common shares through Jefferies LLC. The filing lists the security type as common (related to stock options dated 08/09/2022).
The excerpt also shows multiple completed dispositions by Helen Collins during Feb–Apr 2026, including transactions of 45,000, 29,871, 10,129, 5,000, 40,000, and 5,000 shares on specific dates with corresponding proceeds shown.